期刊论文

Guo, Haiyang;He, Housheng Hansen;Wang, Yuzhuo

英文

Nature Communications

2041-1723

2019

10

1

278

10.1038/s41467-018-08133-6

Princess Margaret Cancer FoundationUniversity of Toronto; Ontario Research Fund [CFI32372]; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC) [498706]; WICC Ontario 20th Anniversary Prostate Cancer Innovation Grant of the CCS [703800]; CIHRCanadian Institutes of Health Research (CIHR) [142246, 152863, 152864, 159567, 153081]; Movember Rising Star awards from Prostate Cancer Canada [RS2014-01, RS2016-1022]; TFRI program project [1062]; NIH/NCI SPORE in Prostate CancerUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50-CA211024]; TFRI New Investigator Award; CIHR New Investigator AwardCanadian Institutes of Health Research (CIHR); OMIR Early Researcher Award; CIHR Graduate Student FellowshipCanadian Institutes of Health Research (CIHR); Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P50CA211024, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P50CA211024, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P50CA211024, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P50CA211024, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P50CA211024, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748] Funding Source: NIH RePORTER

本校为其他机构

Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy. Clinically, genomically and epigenetically, NEPC resembles other types of poorly differentiated neuroendocrine tumors (NETs). Through pan-NET analyses, we identified ONECUT2 as a candidate master transcriptional regulator of poorly differentiated NETs. ONECUT2 ectopic expression in prostate adenocarcinoma synergizes with hypoxia to suppress androgen signaling and induce n...